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Abstract
Background & Aims: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors
for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other
biochemical or histological baseline parameters. We evaluated whether the interplay of both IFNL3 polymorphisms
rs12979860 and rs8099917 together with non-genetic clinical factors contributes to the predictive role of these genetic
variants.
Methods: The cohort comprised 1,402 patients of European descent with chronic HCV type 1 infection. 1,298 patients
received interferon-based antiviral therapy, and 719 (55%) achieved SVR. The IFNL3 polymorphisms were genotyped by
polymerase chain reaction and melting curve analysis.
Results: A significant correlation was found between the IFNL3 polymorphisms and biochemical as well as virologic
predictors of treatment outcome such as ALT, GGT, cholesterol, and HCV RNA levels. In multivariate regression analysis,
IFLN3 SNPs, HCV RNA levels, and the GGT/ALT ratio were independent predictors of SVR. Dependent on the GGT/ALT ratio
and on the HCV RNA concentration, significant variations in the likelihood for achieving SVR were observed in both, carriers
of the responder as well as non-responder alleles.
Conclusions: Our data support a clear association between IFNL3 genotypes and baseline parameters known to impact
interferon responsiveness. Improved treatment outcome prediction was achieved when these predictors were considered in
combination with the IFNL3 genotype.
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Introduction
Hepatitis C virus (HCV) infection is one of the world’s
dominant cause for developing severe liver disease that can
progress to cirrhosis (20–30%) and hepatocellular carcinoma (4%)
[1]. A link between certain disease characteristics and the natural
course of infection and treatment outcome has been demonstrated
in many studies. In these reports, baseline predictors, viral factors,
host determinants and on-treatment factors, have been shown to
influence disease progression and treatment response [2–6].
In previous reports, the gamma-glutamylaminotransferase
(GGT) level was identified as a significant predictor of virologic
response in patients with advanced liver disease [5,7,8]. Other
studies demonstrated a strong association of alanine aminotrans-
ferase (ALT) activity with treatment outcome [9]. We have
reported that an inverse correlation between ALT and GGT
exists, where increased levels of GGT together with ALT flares are
less predictive for non-response than increased GGT levels
without significantly increased ALT levels [5]. Moreover, some
studies reported on interactions between cholesterol metabolism
and interferon responsiveness; low levels of low density lipid (LDL)
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e77530cholesterol were associated with a higher chance of HCV
clearance [10,11]. The mechanisms by which these factors
influence interferon responsiveness remain to be determined.
Several independent genome-wide associated studies (GWAS)
have established strong associations of genetic polymorphisms near
the IFNL3 (interferon lambda 3, IL28B) gene locus, especially
rs12979860 and rs8099917, with treatment outcome [12–16] and
spontaneous viral clearance [17,18,19]. The preferred variants
rs12979860CC and rs8099917TT are significantly associated with
a sustained virologic response (SVR) in HCV genotype 1-infected
patients treated with pegylated interferon (PegIFN) alpha and
ribavirin [6,20,21]. Additionally, some reports provided evidence
that IFNL3 polymorphisms influence the efficacy of different
protease-based triple regimens [22,23].
The functional link and molecular pathways between the IFNL3
polymorphisms and treatment-induced HCV clearance remain far
from clear. Nonetheless, it has been shown that the intrahepatic
expression profiles of interferon stimulated genes (ISG) vary
according to different IFNL3 rs12979860 and rs8099917 geno-
types [16,24]. Patients carrying the favorable IFNL3 genotypes
showed degreased expression levels of genes promoting antiviral
state and an increased expression of ISG suppressors. Low pre-
treatment ISG levels have been found to be associated with a
successful IFN-based therapy whereas patients having high ISG
levels poorly respond to interferon, because the genes are already
activated at an intermediate level and are refractory to further
induction by enthetic IFN [25–28].
However, IFNL3 genotypes may also have an impact on
biochemical parameters such as GGT, ALT and LDL levels, and
thereby provide a link to the well known predictive impact of
baseline predictors of treatment outcome [9]. Indeed, Amanzada
et al. [29] argued that the GGT/ALT ratio may enhance the SVR
predictability of the IFNL3 rs12979860CC genotype.
Recently, a new polymorphism (ss469415590, DG/TT) was
identified between the IFNL2 and IFNL3 genes which creates or
disrupts an open reading frame in a new gene designated
interferon lambda 4 (IFNL4) [30–32]. It was suggested that the
presence of the functional interferon lambda 4 is associated with
impaired HCV clearance and treatment response. However,
because of its high linkage to the IFNL3 rs12969860 SNP in
patients of European descent IFNL4 provides comparable
information.
To further increase our understanding of the relationship
between IFNL3 genotype and treatment outcome, we undertook a
large multicentre, retrospective association study of the IFNL3
polymorphisms rs12979860 and rs8099917 with baseline param-
eters and disease characteristics in HCV infection and defined
their relative importance.
Patients and Methods
Ethics Statement
The study was approved by the Ethics Committees of Medical
Research of the University of Leipzig and of Berlin and the
Human Research Ethics committees of Sydney West Area Health
Service and the University of Sydney in accordance with the 1975
Declaration of Helsinki. The INDIV-1 and INDIV-2 studies were
enrolled at 19 and 20 centers in Germany, respectively.
Independent ethics committee approval had been received at
each center according to the Declaration of Helsinki and the
International Conference on Harmonization/Committee for
Proprietary Medicinal Products ‘‘Good Clinical Practice’’ guide-
lines. All patients provided written informed consent.
Patients
The evaluation cohort (EC) comprised 1000 patients of
European descent with chronic HCV type 1 infection from
Germany (882) and Australia (118). Parts of the cohort were
included in the original GWAS [13] and in the response-guided
individualized tailored treatment regimen of the INDIV-2 study
[33]. The median age was 46 years and 549 (55%) patients were
male. Baseline parameters included aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phosphatase (AP),
gamma-glutamylaminotransferase (GGT), cholesterol, triglycer-
ides, bilirubin and platelets. The AST-platelet-ratio (APRI score)
was calculated using the formula; [APRI score = (AST level
(ULN)/platelet counts (10
9/L))*100] [34]. Liver biopsy was
performed in 848 patients and analyzed by local pathologists at
the clinics. Histological inflammatory activity and fibrosis stages
were scored according to the Desmet-Scheuer [35] and META-
VIR [36] score. Liver steatosis was evaluated by ultrasonography
and by calculating the percentage of lipid droplets containing
hepatocytes of total number of hepatocytes. The characteristics of
the study cohort are shown in Table 1.
Chronic HCV infection was diagnosed by a positive anti-HCV
test in routine diagnostic and by presence of HCV RNA in serum
for more than 6 months. HCV RNA concentration was
determined by qualitative (TMA) and quantitative (bDNA,
CobasH Amplicor Analyzer and high sensitive realtime PCR)
assays. 955 patients were treated with interferon-based therapy
consisting of pegylated interferon (IFN) and ribavirin. They
received the recommended doses and were adherent. Treatment
duration ranged from 24 to 72 weeks depending on the individual
on-treatment response. The standard treatment duration of 48
weeks was applied to 659 (69%) patients. An individualized
treatment with 49–72 weeks was applied to 105 patients (11%) that
were part of the INDIV-2 study [33]. 191 (20%) patients of the
INDIV-2 study had a treatment duration of 24–43 weeks. 435
(46%) patients had sustained virological response (SVR), deter-
mined as undetectable HCV RNA levels 6 months after
completion of therapy. All other patients were classified as patients
with non-sustained virological response (non-SVR). The non-SVR
cohort included patients with either non-response (N=336) or
relapse (n=184). An independent replication cohort (RC) of 402
HCV type 1-infected patients, including 264 Caucasian patients of
the INDIV-1 study [6] was analyzed (Table 1). 343 patients were
treated with dual interferon-based therapy. 239 (70%) patients of
the replication cohort had standard treatment duration of 48
week. An individualized treatment with 24–45 weeks was applied
to 104 (30%) patients. 143 (42%) patients had SVR.
Methods
The DNA samples of all patients were analyzed for the IFNL3
SNPs rs12979860 and rs8099917 SNPs although data for some
parts of the cohort were already available by GWAS [13]. For
genotyping we performed real-time polymerase chain reaction and
melting curve analysis in a Light Cycler 480 System (Roche,
Mannheim, Germany) as described elsewhere [37].
Statistical Analysis
Statistical analysis was performed with SPSS 20.0 (SPSS,
Chicago, Illinois, USA). The significance of associations between
dichotomous data was assessed by Pearson’s x
2 test and
Fischer’s exact test. Continuous data were explored by Mann-
Whitney U-tests. The predictive value of biochemical parame-
ters was analyzed for its receiver operating characteristics
(ROC). The area under the ROC (AUROC) curve with values
close to 1.0 indicates high diagnostic accuracy. The most
IFNL3 and Biochemical Predictors of SVR
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Simple and stepwise multiple regression analyses were per-
formed to determine factors associated with SVR. All tests were
two-sided and p-values less than 0.05 were considered
statistically significant. The odds ratio (OR) and the 95%
confidence interval (CI) were calculated.
Results
Genotype Distribution
In the evaluation cohort (EC) of 1000 patients, the overall
genotype distribution of rs12979860 CC, CT, and TT was 31%,
53%, and 16%, and the distribution of rs8099917 TT, TG and
GG was 50%, 43% and 7%, respectively. The distribution of
rs12979860 and rs8099917 in the replication cohort (RC) was
similar; 29% CC, 53% CT and 18% TT for rs12979860 and 51%
TT, 42% TG and 7% for rs8099917 (Table 2).
Baseline Factors Associated with Variants of rs12979860
and rs8099917
In univariate analyses of both cohorts, carriers of the
homozygote rs12979860CC genotype showed significantly lower
GGT levels, lower GGT/ALT ratio, higher HCV RNA and ALT
levels and less steatosis (EC: p=0.022; RC: p=0.05) compared to
carriers of at least one non-responder T-allele. The rs8099917TT
responder genotype showed a weaker correlation with, low GGT
levels, low GGT/ALT ratios and high HCV RNA and ALT
levels. In the evaluation cohort, there was also an association of
rs12979860CC with elevated cholesterol concentrations
(p=0.009). Figure 1 shows the associations of rs12979860 and
rs8099917 with baseline parameters in the EC (RC in Figure S1).
Multiple regression analysis yielded an association of
rs12979860CC with low GGT/ALT ratios (EC: OR=0.12
[0.05–0.30] p=5.7610
26; RC: OR=0.27 [0.13–0.54]
p=0.0002), high HCV RNA levels (EC: OR=2.40 [1.41–4.08]
Table 1. Patients’ characteristics of the evaluation and replication cohort.
Parameter Evaluation cohort (EC) Replication cohort (RC)
Number of patients 1000 402
Age (years) 46 (39, 54)
a 47 (40, 56)
a
Gender (male/female) 55%/45% 51%/49%
ALT (IU/L) 61 (38, 97)
a 72 (45, 111)
a
AST (IU/L) 43 (29, 65)
a 49 (33, 72)
a
GGT (IU/L) 47 (24, 87)
a 54 (28, 101)
a
GGT/ALT ratio 0.8 (0.4, 1.4)
a 0.7 (0.4, 1.3)
a
AST/ALT ratio 0.7 (0.6, 0.9)
a 0.7 (0.6, 0.9)
a
APRI score n=492 0.8 (0.5, 1.7)
a n=263 0.2 (0.4, 1.0)
a
AP (IU/L) n=505 91 (70, 119)
a n=279 96 (73, 132)
a
Cholesterol (mg/dL) n=632 170 (147, 196)
a n=335 177 (156, 200)
a
Triglycerides (mg/dL) n=612 93 (67, 133)
a n=320 96 (74, 143)
a
Bilirubin (mg/dL) n=665 0.7 (0.4, 0.9)
a n=309 0.6 (0.3, 0.8)
a
Platelets (10
9/L) n=492 203 (157, 249)
a n=263 222 (176, 265)
a
HCV RNA Log10 (IU/mL) n=923 5.8 (5.3, 6.2)
a n=379 5.8 (5.3, 6.2)
a
Steatosis
None/,33%/33%–65%/#100% n=401 16%/64%/17%/3% n=256 65%/26%/6%/3%
Fibrosis stage
F0/F1/F2/F3/F4 n=848 16%/38%/26%/13%/7% n=370 19%/35%/24%/12%/10%
Cirrhosis n=848 9% n=370 11%
Histological activity
A0/A1/A2/A3 n=792 5%/42%44%/9% n=327 8%/46%/40%/6%
Treatment outcome
SVR/NR/Relapse n=955 46%/35%/19% n=343 42%/41%/17%
amedian plus interquartile range (25
th,7 5
th percentile), SVR: sustained virologic response, NR: non-response, IU: international units.
doi:10.1371/journal.pone.0077530.t001
Table 2. Genotype frequencies and sustained virologic
response (SVR) rates of IFNL3 rs12979860 and rs8099917 SNPs
in the evaluation and replication cohort.
Evaluation cohort Replication cohort
Genotype Frequency (%) SVR (%) Frequency (%) SVR (%)
rs12979860 CC 31 65 29 57
CT 53 38 53 35
TT 16 31 18 37
rs8099917 TT 50 58 51 51
TG 43 33 42 30
GG 73 1 73 9
doi:10.1371/journal.pone.0077530.t002
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cholesterol concentration in the evaluation cohort (OR=1.01
[1.00–1.02] p=0.005). The rs8099917TT was associated with a
low GGT/ALT ratio (EC: OR=0.78 [0.64–0.95] p=0.012; RC:
OR=0.63 [0.49–0.82] p=0.0005) and high HCV RNA levels
(EC: OR=1.4 [1.08–1.89] p=0.012; RC: OR=1.5 [1.05–2.15]
p=0.026).
Figure 1. Association of IFNL3 variants with baseline predictors. Association of the IFNL3 rs12979860 and rs8099917 genotypes with the
levels of (A) GGT (IU/mL), (B) ALT (IU/mL), (C) GGT/ALT ratio, (D) pretreatment HCV RNA log10 (IU/mL) and (E) cholesterol (mg/dL) concentration in
the evaluation cohort (EC). Horizontal bars represent the median. Mann-Whitney U-test was used to compare the baseline parameter.
doi:10.1371/journal.pone.0077530.g001
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Treatment Response
Within the group of 955 patients treated with pegIFN and
ribavirin, 435 (46%) patients exhibited a SVR, 184 (19%) showed
a relapse, and 336 (35%) non-response. The SVR rates of the EC
were 65%, 38% and 31% for rs12979860 CC, CT and TT, and
58%, 33% and 31% for rs8099917 TT, TG and GG, respectively.
After combination of rs12979860 and rs8099917, the highest SVR
rates of 66% were for the combined rs12979860CC/
rs8099917TT genotype followed by 49% for rs12979860CT/
rs8099917TT and 32% for rs12979860CT/rs8099917TG. Sim-
ilar results were observed in the RC (Table 2).
In both cohorts, univariate regression analyses revealed that
SVR was significantly associated with rs12979860CC,
rs8099917TT, low values of GGT and AP, low APRI scores
and low HCV RNA levels but high cholesterol concentrations and
platelet counts. Responder patients had longer treatment duration,
were younger and had less steatosis, fibrosis and cirrhosis
compared to the non-responder population. Additionally, lower
ratios of AST/ALT and GGT/ALT and female gender were
associated with treatment response. In stepwise multivariate
regression analyses, low GGT/ALT ratio, and low HCV RNA
concentration as well as rs12979860CC were independent
predictors of SVR. The rs8099917TT also significantly correlated
with SVR (Table 3).
Besides the IFNL3 rs12979860CC and rs8099917TT genotypes,
sensitivity and specificity analysis identified the GGT/ALT ratio
(cut-off value 0.70) and the baseline HCV RNA concentration
(cut-off value 5.8log10) as accurate predictors for SVR (Table S1).
In the evaluation cohort, the SVR rate was 61% when GGT/
ALT ratio was #0.70 and 32% above cut-off and 53% when
HCV RNA concentration was #5.8log10 and 39% in patients with
HCV RNA levels above this cut-off (Fig. 2.A). Best performance
was observed for the combination of IFNL3 with the GGT/ALT
ratio. Within the group of patients carrying the rs12979860CC,
the SVR increased from 65% to 73% when GGT/ALT ratio was
#0.70 (p=0.001). Carriers of the rs8099917TT genotype also had
an increase from 58% to 69% when the GGT/ALT ratio was
#0.70 (p=0.003). When the GGT/ALT ratio was .0.70, the
SVR rates of both homozygous responder variants were signifi-
cantly reduced (rs12979860CC. p=0.005; rs8099917TT:
p=0.0004). When HCV RNA levels were .5.8log10, the SVR
rates degreased in patients carrying the heterozygous or homozy-
gous non-responder T- and G–alleles of rs12979860 (p=0.0004)
and rs8099917 (p=7.2610
26), respectively, (Fig. 2.B–C).
The adjustment for the GGT/ALT ratio (cut-off value 0.70)
and the HCV RNA concentration (cut-off value 5.8log10) further
improved the SVR rates according to the IFNL3 genotypes.
Highest SVR rates were observed in patients carrying the
rs12979860CC (87%) or 8099917TT (80%) variants and having
GGT/ALT ratios and HCV RNA levels below the cut-off values.
In patients carrying at least one T-and G-alleles, the SVR rates
were increased when both the GGT/ALT ratio and HCV RNA
concentration were low. However, independent of the IFNL3
genotypes, the presence of high GGT/ALT ratios correlated with
lower SVR rates although the HCV RNA concentration was
#5.8log10 (Fig. 3). Similar results were observed in the RC.
Discussion
There is growing evidence that genetic variations near the
interferon lambda 3 gene (IFNL3; IL28B) are the most powerful
predictors for sustained virologic response (SVR) in patients with
chronic hepatitis C virus (HCV) infection compared to biochem-
ical or histological parameters [6,12,13,15,20,21]. The mecha-
nisms by which these parameters influence interferon (IFN)
responsiveness remain obscure. In this study we evaluated whether
the interplay of both IFNL3 polymorphisms together with other
Table 3. Univariate and multivariate analyses of factors predictive for sustained virologic response (SVR).
Evaluation cohort Replication cohort
Parameter Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
OR [95% CI] P OR [95% CI] P OR [95% CI] P OR [95% CI] P
Age (years) 0.96 [0.94–0.97] 7.7610
213 0.93 [0.91–0.95] 7.5610
211
HCV RNA Log10 (IU/mL) 0.61 [0.50–0.74] 3.4610
27 0.61 [0.39–0.95] 0.028 0.57 (0.42–0.78] 0.001 0.43 [0.22–0.84] 0.001
GGT (IU/mL) 0.99 [0.98–0.99] 1.4610
214 0.99 [0.99–1.00] 0.0002
GGT/ALT ratio 0.45 [0.38–0.55] 7.2610
216 0.45 [0.24–0.82] 0.010 0.52 [0.38–0.71] 4.5610
25 0.60 [0.40–0.693] 0.021
AST/ALT ratio 0.39 [0.29–0.70] 0.0004 0.42 [0.19–0.91] 0.027
AP (IU/mL) 0.99 [0.99–1.00] 0.003 0.99 [0.99–1.00] 0.001
Platelets (10
9/L) 1.01 [1.00–1.01] 1.6610
25 1.01 [1.00–1.02] 2.9610
26
Cholesterol (mg/dL) 1.01 [1.00–1.01] 0.009 1.01 [1.00–1.02] 0.018
APRI score 0.87 [0.77–0.97] 0.014 0.71 [0.53–0.94] 0.016
Steatosis 0.50 [0.29–0.87] 0.013 0.38 [0.21–0.68] 0.001
Fibrosis stage F3–F4 0.49 [0.37–2.70] 8.2610
27 2.79 [1.68–4.63] 6.9610
25
Cirrhosis 0.27 [0.15–0.50] 3.6610
25 0.10 [0.02–0.44] 0.002
Female sex 1.32 [1.02–1.70] 0.036 1.69 [1.10–2.61] 0.017
Treatment duration 1.03 [1.02–1.04] 1.2610
27 1.04 [1.01–1.06] 0.005
rs12979860CC 3.28 [2.46–4.37] 4.0610
217 4.22 [1.76–10.15] 0.001 2.42 [1.51–3.89] 0.0003 4.57 [1.71–12.22] 0.002
rs8099917TT 2.84 [2.18–3.70] 9.0610
214 2.36 [1.514–4.91] 0.021 2.27 [1.46–3.53] 0.0003 2.33 [1.07–5.08] 0.013
OR: odds ratio, CI: confidence interval, P=p-value, IU: international units.
doi:10.1371/journal.pone.0077530.t003
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activity, the ALT and GGT levels and metabolic factors such as
the serum cholesterol concentration and the occurrence of steatosis
is one reason for the outstanding predictive role of IFNL3 genetic
variants.
In the cohort of 1,402 HCV type 1-infected patients of
European descent we indentified that besides the IFNL3
genotypes, pre-treatment HCV RNA levels, cholesterol concen-
tration as well as levels of GGT and ALT were important baseline
predictors of IFN responsiveness. This is in agreement with
previous studies [5,7,8,10]. However, the intriguing observation
from the present study is the close association of baseline
parameters with IFNL3 genotype.
We proved that patients having low baseline HCV RNA levels
showed the highest response rates, which matched the findings of
other studies [10,39]. Interestingly, but as reported previously, the
favorable IFNL3 rs12979860CC and rs8099917TT genotypes
were strongly associated with high HCV RNA levels [12,21]. Low
HCV RNA levels independently predict SVR only in patients
carrying unfavorable IFNL3 genotypes.
Recently, a new polymorphism (ss469415590, DG/TT) was
identified between the IFNL2 and IFNL3 genes which creates or
disrupts an open reading frame in a new gene designated
interferon lambda 4 (IFNL4) [30–32]. It was suggested that the
presence of the functional interferon lambda 4 is associated with
impaired HCV clearance and treatment response. However, in
patients of European descentIFNL4 provides comparable infor-
mation because of its high linkage to the IFNL3 rs12969860 SNP.
Thus, the IFNL4 is common in patients carrying the rs12979860
T-allele and up-regulates the expression of interferon-stimulated
genes (ISG) before treatment. High pre-treatment intrahepatic
ISG levels have been shown to be associated with poorer ISG
response leading to reduced efficiency of HCV clearance [16,24–
28]. Since interferons alpha and lambda induce a large
overlapping set of target ISGs, the genes are already activated at
an intermediate level and their refractoriness to IFN alpha might
be one mechanism responsible for non-response to IFN-based
therapy observed in chronically infected patients. In vitro and
in vivo studies demonstrated, that continuous exposure of
hepatocytes to interferon results in reduced IFN sensitivity and
the ISG expression maintains on pre-treatment level. Moreover,
any further IFN treatment fails to re-induce transcription of ISGs
[40–42]. However, further research is required to elucidate the
relationship between the IFLN3 genotypes and IFLN4 and the
impact on ISG expression affecting IFN-based treatment response.
We observed that patients exhibiting high cholesterol levels had
an increased likelihood of achieving SVR compared to those with
low levels, similar to previous reports [10,11]. In contrast, low
serum cholesterol concentrations correlated with non-response to
IFN-based treatment [10,11], hepatic steatosis [43], and more
severe fibrosis [44]. Our study revealed a clear correlation between
the homozygous IFNL3 SNPs rs12979860CC, elevated cholesterol
concentrations and a lower prevalence of steatosis, which is in line
with previous reports [45]. This might be explained by the
interaction between the lambda interferons and cholesterol
metabolism on a cellular level. During interferon treatment,
lipoprotein lipase is suppressed by increasing low density
lipoprotein (LDL) cholesterol concentrations and decreasing
triglyceride levels [46]. Cholesterol depletion may inhibit endocy-
tosis of interferon lambda and suppress the activation of interferon
lambda responsive cascades [47]. Carriers of the rs12979860CC
genotype might be less exposed to such disturbances in lipid
metabolism.
Although we still have no answer for the relationship between
GGT levels and IFN responsiveness, high baseline GGT levels
were found to be associated with non-responsiveness to interferon-
based therapies in previous studies [7,8]. We recently demonstrat-
ed [5] an inverse correlation between GGT and ALT, arguing that
GGT elevations that were part of an ALT flare were less predictive
for non-response than those GGT elevations that were seen in
patients with low or even normal ALT levels. Indeed, a GGT to
ALT ratio improved the specificity of response prediction [29]. We
were able to confirm that this ratio was a better predictor
compared to GGT alone. Furthermore, we identified associations
of IFNL3 rs12979860CC and rs8099917TT genotypes with low
GGT values and high levels of ALT. Overall, the correlation
between GGT levels and the rs8099917 SNP was less pronounced
compared to the rs12979860 polymorphism. With increasing
GGT levels, the SVR rates of carriers of at least one copy of the
‘‘non-responder’’ T- and G-allele were up to 3 times lower than
those of patients possessing the ‘‘responder genotypes’’
rs12979860CC and rs8099917TT (Fig. 4). However, carriers of
the homozygous responder IFNL3 genotypes were similarly
affected by the GGT/ALT ratio. In the presence of a high
GGT/ALT ratio, carriers of the IFNL3 rs12979860CC or
rs8099917TT genotype showed reduced IFN responsiveness,
similar to that observed in carriers of the non-responder alleles
exhibiting low GGT/ALT ratios. As recently shown [37], the
combined determination of both IFNL3 SNPs provides more
detailed information with respect to the likelihood of treatment
response in patients carrying the heterozygous rs12979860CT
genotype. Although the additional presence of the rs8099917TT
allele increased the chance of achieving SVR, the pronounced
effect of GGT and ALT activity on IFN responsiveness still
remained (Fig. 4). As a consequence, besides IFNL3 genotypes, the
impact of GGT and ALT activity has to be considered and
inclusion of these parameters into any decision algorithm seems to
be beneficial for response prediction.
SVR rates significantly increased in HCV genotype 1 infection
when protease-inhibitors-based therapies with a backbone of
interferon and ribavirin entered the standard of care. Many factors
involved in IFN responsiveness, such as IFNL3 genotype
[20,23,22], GGT, LDL [48,49] and HCV RNA levels [50], still
maintained their predictive potential. Furthermore, not only the
IFNL3 status, but also GGT levels play a role in some interferon-
free direct-acting antiviral (DAA) regimens [51], highlighting the
relevance of these markers in the mechanisms associated with the
control of HCV infection. Therefore, the association of the IFNL3
SNPs with certain biochemical parameters and their impact on
treatment-induced clearance of infection might be of interest,
independent from treatment strategies.
For correct interpretation of the results it has to be taken in
account that the study has some limitations, because the cohort
included patients of European descent with chronic HCV
genotype 1 infection. Since the frequency of the IFNL3 polymor-
phisms differs between ethnicities the improvement of response
Figure 2. Impact of IFNL3 variants and baseline predictors on sustained virologic response (SVR). SVR rates in the evaluation (EC) and
replication cohort (RC) with regard to (A) GGT/ALT ratio and HCV RNA concentration according to IFNL3 rs12979860 and rs8099917 genotypes in
combination and with (B) GGT/ALT ratio cutoff value of 0.70, (C) HCV RNA concentration cut-off value of 5.8log10 (IU/mL). Pearson’s x
2 test and
Fischer’s exact test were used to compare the SVR rates.
doi:10.1371/journal.pone.0077530.g002
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variants might vary. Especially in patients with Afro-American
ancestry the determination of IFLN4 might be clearly more
informative [30–32]. However, there is evidence that IFNL4 might
even affect HCV clearance and treatment prediction in patients of
European descent [52]. Therefore, further research is required to
Figure 3. Combined determination of IFNL3 variants, GGT/ALT ratio and HCV RNA levels improved sustained virologic response
(SVR) rates. SVR rates in the evaluation (EC) and replication cohort (RC) according to IFNL3 (A) rs12979860 and (B) rs8099917 genotypes after
adjustment for the GGT/ALT ratio (cut-off value 0.70) and HCV RNA concentration (cut-off value 5.8log10).
doi:10.1371/journal.pone.0077530.g003
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PLOS ONE | www.plosone.org 9 October 2013 | Volume 8 | Issue 10 | e77530elucidate the impact of IFNL4 on the genetic association with
biochemical predictors. Furthermore, since the impact of IFLN3
SNPs on treatment response is lower in patients infected with
HCV non-1 genotypes, the association of the polymorphism with
baseline predictors might have different characteristics.
In conclusion, a clear correlation exists between the IFNL3
genotype and the biochemical phenotype of patients of European
descent infected with hepatitis C, including the levels of GGT,
ALT, and cholesterol. These findings may explain the well-known
predictive impact of certain biochemical markers on treatment
outcome, and may provide new insights into the mechanisms by
which innate immunity influences disease. Treatment outcome
prediction can be improved by a combined determination of the
IFNL3 rs12979860 and rs8099917 polymorphisms and baseline
predictors such as GGT, ALT and HCV RNA concentrations,
thereby providing a better tool for decision making. Further work
is required to elucidate the interplay of these parameters that
appear to govern the outcome and the therapeutic response of
patients with chronic HCV infection.
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